The online version of this article (https://doi.org/10.1007/s00125-018-4619-x) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
Paul Welsh and Naomi Rankin are joint first authors. Mark Woodward and Naveed Sattar are joint senior authors.
We aimed to quantify the association of individual circulating amino acids with macrovascular disease, microvascular disease and all-cause mortality in individuals with type 2 diabetes.
We performed a case-cohort study (N = 3587), including 655 macrovascular events, 342 microvascular events (new or worsening nephropathy or retinopathy) and 632 all-cause mortality events during follow-up, in a secondary analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study. For this study, phenylalanine, isoleucine, glutamine, leucine, alanine, tyrosine, histidine and valine were measured in stored plasma samples by proton NMR metabolomics. Hazard ratios were modelled per SD increase in each amino acid.
In models investigating associations and potential mechanisms, after adjusting for age, sex and randomised treatment, phenylalanine was positively, and histidine inversely, associated with macrovascular disease risk. These associations were attenuated to the null on further adjustment for extended classical risk factors (including eGFR and urinary albumin/creatinine ratio). After adjustment for extended classical risk factors, higher tyrosine and alanine levels were associated with decreased risk of microvascular disease (HR 0.78; 95% CI 0.67, 0.91 and HR 0.86; 95% CI 0.76, 0.98, respectively). Higher leucine (HR 0.79; 95% CI 0.69, 0.90), histidine (HR 0.89; 95% CI 0.81, 0.99) and valine (HR 0.79; 95% CI 0.70, 0.88) levels were associated with lower risk of mortality. Investigating the predictive ability of amino acids, addition of all amino acids to a risk score modestly improved classification of participants for macrovascular (continuous net reclassification index [NRI] +35.5%, p < 0.001) and microvascular events (continuous NRI +14.4%, p = 0.012).
We report distinct associations between circulating amino acids and risk of different major complications of diabetes. Low tyrosine appears to be a marker of microvascular risk in individuals with type 2 diabetes independently of fundamental markers of kidney function.
ESM Tables (PDF 659 kb)125_2018_4619_MOESM1_ESM.pdf
Tillin T, Hughes AD, Wang Q et al (2015) Diabetes risk and amino acid profiles: cross-sectional and prospective analyses of ethnicity, amino acids and diabetes in a South Asian and European cohort from the SABRE (Southall And Brent REvisited) Study. Diabetologia 58:968–979 CrossRefPubMedPubMedCentral
Tynkkynen J, Chouraki V, Van der Lee S et al (2018) Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimerʼs disease: a prospective study in eight cohorts. Alzheimers Dement. https://doi.org/10.1016/j.jalz.2018.01.003
ADVANCE Management Committee (2001) Study rationale and design of ADVANCE: Action in Diabetes and Vascular disease – Preterax and Diamicron MR Controlled Evaluation. Diabetologia 44:1118–1120
ADVANCE Collaborative Group, Patel A, MacMahon S et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572 CrossRef
Grossie VB, Yick J, Alpeter M, Welbourne TC, Ota DM (1993) Glutamine stability in biological tissues evaluated by fluorometric analysis. Clin Chem 39:1059–1063 PubMed
Würtz P, Wang Q, Kangas AJ et al (2014) Metabolic signatures of adiposity in young adults: Mendelian randomization analysis and effects of weight change. PLoS Med 11:e1001765
Xu Z, Tan Z, Zhang Q, Gui Q, Yang Y (2014) Clinical effectiveness of protein and amino acid supplementation on building muscle mass in elderly people: a meta-analysis. PLoS One e10:9141
Teslovich TM, Kim DS, Yin X et al (2018) Identification of seven novel loci associated with amino acid levels using single variant and gene-based tests in 8545 Finnish men from the METSIM study. Hum Mol Genet. 27:1664–1674
Druml W, Roth E, Lenz K, Lochs H, Kopsa H (1989) Phenylalanine and tyrosine metabolism in renal failure: dipeptides as tyrosine source. Kidney Int Suppl 27:s282–s286 PubMed
- Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial
Patrick B. Mark
- Springer Berlin Heidelberg
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II